-
Mashup Score: 0Is Finding and Fixing Iron Deficiency in HF Beneficial? - 1 year(s) ago
Ileana Piña interviews Paul Kalra about the IRONMAN trial from the American Heart Association which randomized HF patients with iron deficiency to IV ferric derisomaltose repletion or no infusions.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Does Lipoprotein(a) Play a Causal Role in ASCVD? - 1 year(s) ago
Michelle L. O’Donoghue, MD, MPH, and Stephen J. Nicholls, MBBS, PhD, discuss the evidence on lipoprotein(a) and its potential role in atherosclerosis and aortic stenosis.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
With targeted therapies on the horizon @DrM_ODonoghue & @ProfSNicholls discuss Lp(a) and its role in #ASCVD #AHA22 https://t.co/Eg1WvZKbxo https://t.co/AlrVu6apk6
-
-
Mashup Score: 0
CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be a safe and effective alternative compared with the current standard of care for this age group, researchers reported. Edoxaban (Savaysa, Daiichi Sankyo) is FDA-approved for use in adults with atrial fibrillation and other conditions that increase risk for thromboembolism.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Portman said edoxaban “may provide an advantage” for children compared with other options, considering difficulties with enoxaparin injections and food and drug interactions with warfarin. @MPortmanMD @seattlechildren #AHA22 #cardiotwitter https://t.co/Kji8grYOsX
-
-
Mashup Score: 0
CHICAGO — In the U.S. and U.K., exposure to environmental factors such as lead and ambient particulate matter may correlate to increased CV death, according to a 30-year analysis of mortality data.Uniquely, CV-related death was more common among populations with lead exposure in the U.S. compared with the U.K., whereas CV-related death was more common in particulate matter-exposed
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: CV-related death was more common among populations with lead exposure in the U.S. compared with the U.K., whereas CV-related death was more common in particulate matter-exposed populations in the U.K. @AnoopTitus @AHAMeetings #AHA22 #Cardiotwitter https://t.co/eqmstoxx6i
-
-
Mashup Score: 0
CHICAGO — In the U.S. and U.K., exposure to environmental factors such as lead and ambient particulate matter may correlate to increased CV death, according to a 30-year analysis of mortality data.Uniquely, CV-related death was more common among populations with lead exposure in the U.S. compared with the U.K., whereas CV-related death was more common in particulate matter-exposed
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: CV-related death was more common among populations with lead exposure in the U.S. compared with the U.K., whereas CV-related death was more common in particulate matter-exposed populations in the U.K. @AnoopTitus @AHAMeetings #AHA22 #Cardiotwitter https://t.co/eqmstoxx6i
-
-
Mashup Score: 0
CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be a safe and effective alternative compared with the current standard of care for this age group, researchers reported. Edoxaban (Savaysa, Daiichi Sankyo) is FDA-approved for use in adults with atrial fibrillation and other conditions that increase risk for thromboembolism.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: Portman said edoxaban “may provide an advantage” for children compared with other options, considering difficulties with enoxaparin injections and food and drug interactions with warfarin. @MPortmanMD @seattlechildren #AHA22 #cardiotwitter https://t.co/Kji8grYOsX
-
-
Mashup Score: 0
CHICAGO — For children with rare heart conditions that increase risk for thromboembolism, daily edoxaban may be a safe and effective alternative compared with the current standard of care for this age group, researchers reported. Edoxaban (Savaysa, Daiichi Sankyo) is FDA-approved for use in adults with atrial fibrillation and other conditions that increase risk for thromboembolism.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
For children with rare heart conditions that increase risk for #thromboembolism, daily #edoxaban may be a safe and effective alternative vs. current standard of care for this age group @MPortmanMD @seattlechildren @AHAMeetings #AHA22 #cardiotwitter https://t.co/Kji8grYOsX
-
-
Mashup Score: 0
CHICAGO — In the U.S. and U.K., exposure to environmental factors such as lead and ambient particulate matter may correlate to increased CV death, according to a 30-year analysis of mortality data.Uniquely, CV-related death was more common among populations with lead exposure in the U.S. compared with the U.K., whereas CV-related death was more common in particulate matter-exposed
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In the U.S. and U.K., exposure to environmental factors such as lead and ambient particulate matter may correlate to increased CV death, according to 30-year mortality data @AnoopTitus @St_Vincent_Hosp @AHAMeetings #AHA22 #Cardiotwitter https://t.co/eqmstoxx6i
-
-
Mashup Score: 3AHA Scientific Sessions 2022 Highlights - 1 year(s) agoSource: YouTubeCategories: Cardiologists, Latest HeadlinesTweet
-
A special @YaleCardiology grand rounds, where CV fellows Tom Breen and Inga Melvinsdottir are leading an update from #AHA22 #STRONGHF #BESTCLI #ISCHEMIA_EXTEND #EMPAKidney #DCP #CRISPR LIVE here: https://t.co/2oEqbizsB4 @ericjvelazquez @edwardmillermd @YaleMed https://t.co/eIgMq4CIY1
-
-
Mashup Score: 0
CHICAGO — Survival rates have almost doubled for children who experienced in-hospital cardiac arrest during the last 20 years, with the greatest gains in children who experienced cardiac arrest after cardiac surgery, researchers reported.The data were presented at the American Heart Association Scientific Sessions.
Source: www.healio.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
ICYMI: “Children have higher rates of survival after in-hospital cardiac arrest than previously reported, which is an amazing feat in the resuscitation science and quality field,” @MGardnerMD @PennMedicine @ChildrensPhila @AHAMeetings #AHA22 https://t.co/vCiE4zquOP
-
Ileana Piña interviews Paul Kalra about the IRONMAN trial from the @American_Heart which randomized HF patients with iron deficiency to IV ferric derisomaltose repletion or no infusions. https://t.co/fLoGBdc2IW #AHA22 #Cardiology #CardioTwitter #AHA2022 https://t.co/yjG4AsTpD0